Intraperitoneal Nanotherapy for Metastatic Ovarian Cancer Based on siRNA-Mediated

Suppression of DJ-1 Protein Combined with a Low Dose of Cisplatin
Introduction
Ovarian cancer is the deadliest gynecologic malignancy. 1 The high mortality of ovarian cancer stems from its unique metastatic behavior not shared with other cancers. Following exfoliation at primary tumor sites, ovarian cancer cells are disseminated within the abdominal cavity via a peritoneal fluid. 2, 3 As a result, malignant cells encase the reproductive organs, bladder, sigmoid colon, and omentum, leading to the accumulation of abdominal ascites and severe pain. 3 The standard therapy for patients with metastatic ovarian cancer consists of primary debulking surgery followed by platinum-taxane based chemotherapy. 1, 4 Due to the diffuse nature of ovarian cancer, surgery rarely enables the complete removal of all metastases, and the incorporation of chemotherapy is of utmost importance to eliminate any residual tumors. 4, 5 The standard chemotherapy regimen for ovarian cancer is a combination of two or more platinum and taxane drugs administered intravenously (IV) or intraperitoneally (IP) for three to six cycles. 6 Application of multiple chemotherapeutic agents allows the oncologists to target a variety of oncogenic pathways that promote growth and dissemination of primary tumor in the form of metastases. Clinical studies revealed that IP chemotherapy is more efficient than IV chemotherapy, but it also causes more deleterious side effects making some patients discontinue their treatment before its completion. 7 Enhanced therapeutic efficacy and the severe side effects that encompass IP chemotherapy are due to the high concentrations of the chemotherapeutic agents that can be achieved within the peritoneal cavity. 7 Therefore, there is an urgent need to develop novel IP therapies that allow for a reduction in the number of cycles and doses of chemotherapeutic drugs used in the treatment of ovarian cancer, while improving treatment outcomes and efficacy. Identification and suppression of a single multifunctional protein,
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responsible for malignant proliferation, invasion, chemoresistance, and overall cellular survival, is a promising therapeutic avenue that would satisfy all the aforementioned needs.
DJ-1 is a multifunctional protein that has recently been implicated as a key oncogenic driver and biomarker for various cancers, including ovarian cancer. 8, 9 Previous studies revealed that DJ-1 is expressed in more than 80% of cases of advanced ovarian carcinoma at all anatomical sites. 10 It was also documented that increased DJ-1 expression positively correlates with both lower survival in ovarian cancer patients and enhanced the resistance of ovarian cancer cells to platinum-based drugs. 11-13 DJ-1 has been shown to modulate (either directly or indirectly)
various cellular pathways that support and promote survival, growth, and invasion of cancer cells. 12, 13 It is known that DJ-1 binds to and downregulates the activity of phosphatase and tensin homolog (PTEN), a protein that functions as a biological brake for Akt pathways, thus increasing the growth, proliferation, and migration of tumor cells. 8, 14, 15 Furthermore, DJ-1 directly inhibits tumor suppressor protein 53 (p53), a cell cycle regulation protein responsible for cell cycle arrest. 16 DJ-1 enhances the activity of NRF2 -an antioxidant protein that, when translocated to the nucleus, upregulates a cohort of factors responsible for modulating the cellular redox homeostasis in response to elevated levels of intracellular reactive oxygen species (ROS). [17] [18] [19] Finally, DJ-1 upregulates glutamate cysteine ligase -the rate-limiting enzyme in glutathione synthesis further increasing cellular antioxidant defenses. 20 We have recently demonstrated in vitro that DJ-1 is highly overexpressed in ovarian cancer cells and its siRNA-mediated suppression substantially decreases cell proliferation, viability, and migration. 11 Moreover, we discovered that DJ-1 suppression in combination with a low dose of cisplatin provides a superior therapeutic response in the studied ovarian cancer cell lines.
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Therefore, we hypothesized that novel IP therapy based on siRNA-mediated DJ-1 suppression combined with low doses of cisplatin could provide a promising treatment modality for metastatic ovarian cancer. Herein, we report the first use of DJ-1 suppression as a therapeutic approach for the treatment of metastatic ovarian cancer.
Methods
Development of a murine model for metastatic human ovarian cancer
Animal studies were performed according to the Humane Care 
Synthesis and characterization of a nanoplatform for siRNA delivery
The LHRH-targeted nanoplatform for DJ-1 siRNA delivery was prepared and characterized according to our developed procedures (Supplementary Materials).
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Evaluation of the nanoplatform efficiency to suppress the targeted protein in vivo
Three weeks following ES-2-luc inoculation, five mice were IP injected twice per week (Tuesday and Friday) with 0.5 mL of nanoparticles loaded with DJ-1 siRNA at a 50 μM concentration. In the control group, five mice were injected with saline. 24 h after the second injection, mice were euthanized, and both solid tumors and ascites fluid were collected. A portion of the solid tumors was digested using a tissue homogenizer in 250 μL of RIPA buffer.
The ascites cells were centrifuged at 3,500 rpm for 3 min, and the cell pellet resuspended in 250 μL of RIPA buffer. The immunoblots were performed according to our previously published protocol.
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Animals dosing regimen
The control and cisplatin monotherapy groups were IP dosed once a week at the beginning of each week (Monday). The control group was given a normal saline injection at a volume of 1 mL. The cisplatin monotherapy group was given an IP injection of cisplatin at a concentration of 0.05 mg (1.85 mg/kg), in a volume of 1 mL. Finally, the DJ-1 monotherapy group was IP dosed twice per week (Tuesday and Friday) with nanoparticles at a 50 μM siRNA concentration in a volume of 0.5 mL. For the combinatorial treatment group, the cisplatin and DJ-1 monotherapy groups dosing regimens were combined. All treatment groups were given their respective therapies for a total of 3 weeks.
Statistical Analysis
The data were analyzed using descriptive statistics and presented as mean values ± standard deviation (SD) from 3-6 independent measurements. The comparison among groups was performed by the independent sample Student's t-test. The difference between variants was considered significant at p < 0.05. Kaplan-Meier estimator curves and median survival times were performed using "survfit" in the "survival" R package. Log-Rank-Test for differences between groups was performed using "survdiff" in "survival." Hazard ratios for treatments and overall Likelihood Ratio Test were calculated using "coxph" in "survival." The proportional hazards assumptions were confirmed using the Z:ph test "cox.zph" in "survival." Fourth, ES-2 cells exhibit moderate resistance to platinum chemotherapeutic agents.
Results
Development and characterization of a murine model for metastatic human ovarian cancer
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Platinum resistance is of an immense clinical importance as it has been reported that a majority of patients with cancer relapse show either a decreased sensitivity or complete resistance to platinum chemotherapy. 27 Fifth, ES-2 cells have been shown to overexpress the luteinizing hormone releasing hormone receptor (LHRHR) used for growth and proliferation. 28 34 We anticipate the LHRH-targeted nanoplatform prepared and evaluated in the present study can be potentially extended to a variety of ovarian tumors.
Synthesis and characterization of a nanoplatform for siRNA delivery
The instability in blood and low accumulation in the targeted tissue after systemic administration and limited internalization into cellular cytoplasm are the major issues preventing the application of siRNA for the developed therapeutic approach. 35 Therefore, we have engineered a delivery system for the transportation of the DJ-1 siRNA to the ovarian cancer tumors after IP administration ( Figure 2 ). The core of the system is based on the nanoparticles formed as a result of the spontaneous electrostatic complexation between the DJ-1 siRNA and generation 4 PPI dendrimer (PPI G4). 36 The positively charged primary amines of the PPI G4 interact with the negatively charged phosphate groups of the siRNA's backbone (Figure 2A ). An excess of the dendrimer provides encapsulation of siRNA inside of nanoparticles, which in turn protects the siRNA against Ribonuclease-mediated degradation in the serum and facilitates cellular uptake. 21 The gel retardation assay validated the complete complexation of the siRNA by PPI G4 at nitrogen to phosphate (N/P) ratio of 2 ( Figure S1 ), indicating that the resulting nanoparticles contain 0.38 nanomoles of siRNA per 1 nanomole of PPI G4. According to DLS analysis, the formed nanoparticles featured an average hydrodynamic diameter of 100.8 ± 15.5 nm ( Figure   S2 ) and a narrow size distribution (polydispersity index (PDI) = 0.13 ± 0.07). The protonated amines in the dendrimer structure, which are important for siRNA complexation, introduce positive charge onto the surface of nanoparticles (+28.0 ± 4.1 mV). A positively charged surface could promote nanoparticle aggregation in the blood, due to electrostatic association with negatively charged serum proteins. 37, 38 To avoid this, we have modified the surface of nanoparticles with polyethylene glycol (PEG), which contains a thiol-reactive maleimide and amine-reactive NHS ester on the opposite ends. 21 The modification has been carried out by coupling NHS groups of PEG to amino groups on the nanoparticle surface via amide bonds ( Figure 2B ). Finally, the LHRH peptide was conjugated to the distal end of the PEG moiety by coupling its MAL group to a thiol group (SH) presented in the peptide structure ( Figure 2C ). 21 The presence of LHRH peptide on the nanoparticles surface was confirmed by Bicinchoninic acid protein assay according to the manufacturer's protocol and our published procedure. 21 The Figure 3E and F) . 39 In addition, the serum levels of blood electrolytes were evaluated as an indicator of major organ toxicity ( Figure 3G ). 40 The concentrations of surrogate markers and blood electrolytes in mice injected with saline (control) or the nanoparticles were similar ( Figure 3E and G) and within the normal ranges, 41 indicating that the developed nanoparticles do not exhibit any acute toxicity.
The DJ-1 siRNA's ability to suppress the targeted protein in both solid tumors and ascites was Figure   S4 ). DJ-1 has also been reported to promote cancer cells growth and resistance to chemotherapeutic drugs by sequestering tumor suppressor protein p53 and consequently inhibiting the apoptotic p53-Bax-Caspase pathway. 8, 11, 16 It was consistently observed that the levels of p53 and pro-apoptotic cleaved caspase 3 (CASP-3) were substantially elevated in both ascites and solid tumors following the siRNA-mediated attenuation of DJ-1 (Figure 4 and Figure   S4 ). Moreover, changes in the expression of the above-mentioned proteins in solid tumors were confirmed by immunohistochemistry ( Figure S5 ).
Design and evaluation of the combinatorial therapy for metastatic ovarian cancer
The developed combinatorial treatment consists of two monotherapies administered sequentially via IP route for three cycles: (1) the chemotherapy agent, cisplatin, and (2) siRNA-loaded nanoparticles aimed to suppress DJ-1 protein ( Figure 5 ). We reduced the last mentioned IP dose of cisplatin for our therapy by a factor of 10 resulting in 0.05 mg (1.85 mg/kg), which is reported to be safe in nude mice. 45 . In considering the accepted dosing regimen, scaled for species' size variability, the combinatorial treatment included an IP injection of cisplatin dosed at 0.05 mg (1.85 mg/kg) once a week for 3 weeks (three cycles) on day one of each cycle (Monday, Figure 5 ).
Our in vitro studies demonstrated that siRNA therapy must be initiated prior to cisplatin administration in order to achieve the superior therapeutic outcome ( Figure S6 ). Such regimen is due to the long half-life (~24-30 h) of DJ-1; 17, 46 thus siRNA-mediated silencing of DJ-1 transcript is needed before chemotherapy to substantially deplete its basal levels in cancer cells.
To achieve and maintain steady-state suppression of DJ-1 protein, siRNA therapy was initiated one week prior to, and continued during cisplatin-based chemotherapy via IP injections of siRNA-loaded nanoparticles on Tuesday and Friday of each week during 3 weeks (total of 6 injections, Figure 5 ). Our in vivo data provided in Figure 4 validates that two IP injections of siRNA-loaded nanoparticles administered 3 days apart provided a substantial decrease of DJ-1 protein levels in both solid tumors and ascites. The siRNA dosing regimen was based on our previous in vitro data, which demonstrated that following one siRNA transfection, DJ-1 protein suppression lasts for more than 3 days in cultured ovarian cancer cells.
11
The efficacy of our combinatorial therapy was assessed by long-term survival studies and compared to the corresponding monotherapies and non-treated animals.
The following control groups were tested ( two IP injections of siRNA-loaded nanoparticles on Tuesday and Friday of each treatment week (total of 6 injections). All treatments were initiated one week after inoculation of ES-2 ovarian cancer cells into mice and animals were monitored for fitness and survival during the study.
Additonally, both body weight and bioluminescence images of mice were recorded weekly.
Three weeks following treatment initiation, mice injected with saline displayed signs of severe ascites characterized by obvious abdominal distension, the rapid increase in body weight ( Figure   S7 ), lethargy and impaired mobility. Also, the tumors were widely disseminated accross the abdominal cavity as indicated by bioluminescence imaging (Figure 6 ). Consequently, animals had to be euthanized according to the approved protocol. The cisplatin monotherapy prolonged the median survival time of mice to 6 weeks whereas that of the saline-treated group was 3 weeks after the start of treatment (Table 1, Figures 6 and 7) . Interestingly, the siRNA monotherapy further extended the survival time of mice by 2 weeks over that of cisplatin alone.
Finally, ovarian cancer tumors were completely eradicated from the mice treated with a combinatorial therapy, and there was no cancer recurrence detected during the duration of experiment ( Figure 6 ). The animals from this group were observed for 35 weeks and euthanized.
Because a single non-cancer-related death occurred in this group, median survival time could not be calculated but would be greater than 35 weeks ( Figure 7 and Table 1 ).
Hazard Ratios, a measure of the effect of treatment on an outcome of interest over time, were calculated for each group. Cisplatin monotherapy displayed a Hazard Ratio of 0.10306 (95% CI:
0.02151-0.49365), a reduction in the hazard (death probability at a given time point) by 89.7% compared to saline-treated animals (Table 1) (Table 1) . Mice treated with siRNAloaded nanoparticles and combinatorial treatment at any given time point during the study were 99.1% and 99.9% less likely to die at the following time point compared to mice in the saline treated group, respectively. The calculated hazard ratios show that the combinatorial therapy had the greatest reduction in hazard of all the treatment groups, meaning that cisplatin combined with DJ-1 siRNA has the most pronounced effect on ovarian cancer cell death leading to increased survival within the combinatorial group. An overall difference between the four treatment groups was found to be significant (LRT: 
Discussion
An efficient approach for ovarian cancer treatment can be developed by combining two or more therapeutic agents at their non-toxic doses in a manner wherein cytotoxic mechanisms of action synergistically complement each other ideally affecting multiple pathways that lead to the cancer growth and survival. Here, we have combined the first line chemotherapy agent cisplatin and a novel siRNA-based gene therapy focused on the suppression of the multifunctional DJ-1 protein.
Their cytotoxic mechanisms of action target multiple distinctly different intracellular pathways and thus make it extremely difficult for the cancer cells to compensate and upregulate antiapoptotic pathways in order to survive. Cisplatin primarily stops the proliferation of cancer cells by crosslinking DNA, usually at guanine residues, thereby disrupting DNA repair mechanisms, causing DNA damage, and subsequently inducing apoptosis when repair proves impossible. 47 Several studies also reported that cisplatin can induce an intracellular level of toxic ROS via the reduction of the mitochondrial membrane potential. 11, 48 In contrast to cisplatin, DJ-1 suppression by siRNA can simultaneously interfere with the expression of multiple oncogenic proteins responsible for ovarian cancer cells survival, migration, proliferation, and resistance to platinumbased drugs. 8 Our data indicate that DJ-1 silencing correlates with a significant upregulation of p53 in tumors and ascites, a protein that negatively affects proliferation and viability of malignant cells. 8, 16 We also validated that siRNA-mediated DJ-1 suppression is accompanied by downregulation of p-Akt levels. Akt phosphorylation promotes survival and migration of cancer cells while reducing their apoptosis. 8, 14, 15 Finally, we revealed that DJ-1 suppression leads to a substantial reduction in the intracellular level of NRF2. It is known that enhanced levels of NRF2 protect cancer cells from ROS-mediated death. 20, 42 Our present in vivo data suggests that siRNA-mediated suppression of DJ-1 can be a potent strategy to enhance the anticancer effects of conventional chemotherapy while reducing severe side effects. Taking siRNA monotherapy provides higher efficacy than cisplatin regarding decreasing cancer cells viability, proliferation, and migration while enhancing intracellular ROS production and cell cycle arrest. 11 Although treatment of mice with metastatic ovarian cancer by DJ-1 siRNA monotherapy significantly reduced the growth rate of tumors in comparison to cisplatin treatment, complete remission of cancer was not attained and mice had to be euthanized at the end of week 8. The observed therapeutic outcome could be explained by the fact that siRNA treatment was completed at the end of week 3 and due to only temporary effects of siRNAs on target genes (several days). 11, 12 As a result, DJ-1 protein suppression by three cycles of siRNA therapy may not last long enough to kill all the cancer cells. In contrast, combinatorial siRNAmediated DJ-1 therapy with a low dose of cisplatin completely eradicated ovarian cancer tumors from the mice, and no cancer recurrence was detected during the 35-weeks trial. These results strongly suggest that the suppression of DJ-1 protein may dramatically enhance the therapeutic activity of cisplatin and could be explored as a therapeutic target in combination with other chemotherapy agents.
In conclusion, this work validates therapeutic efficacy of a novel combinatorial treatment for metastatic ovarian cancer and highlights the importance of selecting therapeutic agents whose cytotoxic mechanisms of action complement one another in the context of a treatment regimen.
Our animal studies establish a solid foundation for the potential application of DJ-1 siRNA therapy as an adjuvant therapeutic option to reinforce the existing conventional chemotherapeutic regimens in order to attain decreased systemic side effects and increase the efficacy of traditional anti-cancer interventions.
Appendix A. Supplementary Materials
Supplementary materials to this article can be found online. 
Graphical Abstract
We have developed and validated combinatorial treatment for metastatic ovarian cancer which consists of two monotherapies administered sequentially via intraperitoneal route for three cycles: (1) siRNA-loaded nanoparticles aimed to suppress DJ-1 protein, and (2) the chemotherapy agent, cisplatin. DJ-1 suppression by siRNA can simultaneously interfere with the expression of multiple oncogenic proteins responsible for ovarian cancer cells survival, migration, proliferation and resistance to platinum-based drugs. The developed therapy eradicated metastatic ovarian cancer tumors from the mice, and there was no cancer recurrence detected during the duration of the study.
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